aibioAlterity reports A$54.56M cash after A$20M placement in the quarter
Tickers ATH
Operating cash outflows were A$5.34M for the quarter ended 30 September 2025. The company says the placement was led by healthcare-focused funds.
Key facts
- Company
- Alterity Therapeutics Ltd. (ASX: ATH)
- News type
- Financings
- Primary source
- Alterity Therapeutics Ltd. 6-K (2025-10-31)
The quarter's cash
Alterity Therapeutics Limited, whose tickers are ATH and ATHE, reported a cash balance of A$54.56M on 30 September 2025. The figure comes from its Appendix 4C quarterly cash flow report, which it furnished to the SEC as an exhibit to a Form 6-K on 31 October 2025. At the end of the previous quarter the company held A$40.66M.
Operating cash outflows for the quarter were A$5.34M, and payments for research and development were A$3.974M. The report also lists A$108k paid to related parties and their associates, which the company says is disclosed under ASX Listing Rule 4.7C. Financing activities brought in A$19.235M, net of costs. Without that inflow, the balance would have fallen in the quarter.
The company says it raised a total of A$20M in gross proceeds from a strategic placement. The release describes the placement as led by high-quality healthcare-focused funds, and says the money will advance its programs.
Who raised the money
The release names no placement agent, lead manager, broker or underwriter for the placement, and it names no legal counsel for it. The only people named in its contact details are investor relations and media representatives. The release does not say which bank or adviser, if any, arranged the placement.
What the release reports on ATH434
ATH434 is designed to block the accumulation and aggregation of alpha-synuclein, a protein implicated in neurodegeneration, according to the company's 20-F filed on August 29, 2025. The company has been granted Fast Track designation from the US Food and Drug Administration for ATH434 in multiple system atrophy, a rare Parkinsonian disorder, and orphan drug designation for the same indication.
The release presents a new analysis of the modified UMSARS I data from the double-blind ATH434-201 Phase 2 trial. The analysis was presented after the quarter ended, and it adds baseline orthostatic blood pressure change as a covariate. With that covariate, the company reports a strengthened efficacy signal in the 75 mg group of negative 2.8 points at 52 weeks, a relative treatment effect of 35%. The release says baseline differences in severe orthostatic hypotension "largely explains the different responses" in the 50 mg and 75 mg groups. It also says placebo patients worsened on average by about 6 points over 52 weeks on a patient-reported orthostatic hypotension symptom scale, while the 50 mg and 75 mg groups were stable.
The release also highlights ATH434-202, an open-label Phase 2 trial in more advanced MSA. It says a key objective was met, with the 75 mg dose showing efficacy comparable to the double-blind study. Open-label means the trial had no placebo arm, so the release offers no placebo comparison for that study.
The company says it is working with the FDA on a series of Type C meetings covering nonclinical and manufacturing data, and that an End-of-Phase 2 meeting is expected in mid-2026. The release says agreement with the FDA on those elements is critical to starting a Phase 3 trial in MSA. No Phase 3 trial has started, and the release gives no date for one.
The $2.4 billion figure
The company says an independent commercial assessment indicates a potential worldwide peak sales opportunity of USD$2.4 billion for ATH434 in MSA, "if approved." The release says physicians surveyed noted the importance of inhibiting alpha-synuclein aggregation. It does not give the survey size, the method or the assumptions behind the figure, so the number cannot be checked from the release. It is a peak sales estimate for a drug that has no approval and whose Phase 3 plan is still being discussed with the FDA.
What the company still has to fund
The release gives a cash balance but no cash runway figure, and it does not say how much the Phase 3 program would cost. The quarter's research and development payments were A$3.974M, against a balance of A$54.56M. The company's next steps depend on FDA meetings that the release says are still ahead. A reader can see the cash, the placement and the burn for one quarter, but not how long the balance lasts once trial costs rise.